Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer

Table 5 Prognostic factors by log-rank test and univariate survival analysis ^a in present study

Factors	Group	Number	Median OS^b(months)	Log-rank testpvalue	Univariate analysispvalue
Age	<57 years	24	33.2	0.876	0.853
Age	≧57 years	22	30.8	0.876	0.853
Gender	Male	35	31.3	0.949	0.932
Gender	Female	11	32.8	0.949	0.932
ECOG ^c performance status	0-1	41	32.4	0.906	0.887
ECOG ^c performance status	2	4	29.6	0.906	0.887
Pathology	Squamous-cell lung cancer	28	26.4	0.013	0.017
Pathology	Non-squamous cell lung cancer	18	45.1	0.013	0.017
Staging after surgery ^d	II	11	35.2	0.654	0.613
Staging after surgery ^d	III	35	30.0	0.654	0.613
Chemotherapy regimen	TP	31	33.7	0.393	0.308
Chemotherapy regimen	TC/TO	15	30.5	0.393	0.308
Irradiation dose	≧60 Gy	40	33.6	0.505	0.496
Irradiation dose	<60 Gy	16	29.3	0.505	0.496

^a: Cox’s proportional hazards regression model; ^b: overall survival; ^c: Eastern Corporative Oncology Group; ^d: According to the AJCC 6^th staging system.

ISSN: 1471-2407